JP2016539127A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539127A5 JP2016539127A5 JP2016533569A JP2016533569A JP2016539127A5 JP 2016539127 A5 JP2016539127 A5 JP 2016539127A5 JP 2016533569 A JP2016533569 A JP 2016533569A JP 2016533569 A JP2016533569 A JP 2016533569A JP 2016539127 A5 JP2016539127 A5 JP 2016539127A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- optionally
- sarna
- patient
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 19
- 229940078677 Sarna Drugs 0.000 claims 15
- 210000004027 cells Anatomy 0.000 claims 11
- 230000014509 gene expression Effects 0.000 claims 9
- -1 MET Proteins 0.000 claims 8
- 230000003463 hyperproliferative Effects 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 230000022983 regulation of cell cycle Effects 0.000 claims 4
- 229920002395 Aptamer Polymers 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 210000003494 Hepatocytes Anatomy 0.000 claims 3
- 206010024324 Leukaemias Diseases 0.000 claims 3
- 108020004459 Small Interfering RNA Proteins 0.000 claims 3
- 239000002924 silencing RNA Substances 0.000 claims 3
- 102100008329 FASN Human genes 0.000 claims 2
- 101710008102 FASN Proteins 0.000 claims 2
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims 2
- 210000004185 Liver Anatomy 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010025310 Other lymphomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 2
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 2
- 239000000412 dendrimer Substances 0.000 claims 2
- 229920000736 dendritic polymer Polymers 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 229920001239 microRNA Polymers 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920000962 poly(amidoamine) Polymers 0.000 claims 2
- 210000004881 tumor cells Anatomy 0.000 claims 2
- 101710010925 17.1 Proteins 0.000 claims 1
- 102100011408 ACACA Human genes 0.000 claims 1
- 101700056202 ACACA Proteins 0.000 claims 1
- 102100011407 ACACB Human genes 0.000 claims 1
- 101700081524 ACACB Proteins 0.000 claims 1
- 102100010284 ADAM17 Human genes 0.000 claims 1
- 101710043085 ADAM17 Proteins 0.000 claims 1
- 101700006234 AKT1 Proteins 0.000 claims 1
- 102100001248 AKT1 Human genes 0.000 claims 1
- 102100001249 ALB Human genes 0.000 claims 1
- 102100007747 ANGPT2 Human genes 0.000 claims 1
- 101710043855 ANGPT2 Proteins 0.000 claims 1
- 102100017826 APOC3 Human genes 0.000 claims 1
- 101700049216 APOC3 Proteins 0.000 claims 1
- 210000000577 Adipose Tissue Anatomy 0.000 claims 1
- 210000003486 Adipose Tissue, Brown Anatomy 0.000 claims 1
- 210000000593 Adipose Tissue, White Anatomy 0.000 claims 1
- 210000003719 B-Lymphocytes Anatomy 0.000 claims 1
- 102100013894 BCL2 Human genes 0.000 claims 1
- 108060000885 BCL2 Proteins 0.000 claims 1
- 102100015655 BCL2L1 Human genes 0.000 claims 1
- 101710032374 BCL2L1 Proteins 0.000 claims 1
- 102100007324 BIRC2 Human genes 0.000 claims 1
- 101700082851 BIRC2 Proteins 0.000 claims 1
- 102100007326 BIRC5 Human genes 0.000 claims 1
- 102100008990 CASP8 Human genes 0.000 claims 1
- 101700075287 CASP8 Proteins 0.000 claims 1
- 102100016449 CCL5 Human genes 0.000 claims 1
- 101700063377 CCL5 Proteins 0.000 claims 1
- 102100019529 CCND1 Human genes 0.000 claims 1
- 102100019530 CCND2 Human genes 0.000 claims 1
- 101700059002 CCND2 Proteins 0.000 claims 1
- 108010045374 CD36 Antigens Proteins 0.000 claims 1
- 102100004728 CDH1 Human genes 0.000 claims 1
- 101700016900 CDH1 Proteins 0.000 claims 1
- 102100005704 CDH13 Human genes 0.000 claims 1
- 101710032695 CDH13 Proteins 0.000 claims 1
- 102100002974 CDKN1A Human genes 0.000 claims 1
- 102000033243 CDKN2A Human genes 0.000 claims 1
- 102100019883 CETP Human genes 0.000 claims 1
- 101700077539 CETP Proteins 0.000 claims 1
- 102100013000 CFLAR Human genes 0.000 claims 1
- 101700079603 CFLAR Proteins 0.000 claims 1
- 208000005623 Carcinogenesis Diseases 0.000 claims 1
- 108010058546 Cyclin D1 Proteins 0.000 claims 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 claims 1
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 claims 1
- 102000000577 Cyclin-Dependent Kinase Inhibitor p27 Human genes 0.000 claims 1
- 108010016777 Cyclin-Dependent Kinase Inhibitor p27 Proteins 0.000 claims 1
- 102100007858 DGAT2 Human genes 0.000 claims 1
- 101700003156 DGAT2 Proteins 0.000 claims 1
- 101700011568 DIB1 Proteins 0.000 claims 1
- 102100000248 DLC1 Human genes 0.000 claims 1
- 101710031659 DLC1 Proteins 0.000 claims 1
- 101700079711 DLEC1 Proteins 0.000 claims 1
- 101710031844 DYNLL1 Proteins 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 101710009915 FAD7 Proteins 0.000 claims 1
- 102100007583 FADD Human genes 0.000 claims 1
- 101700015998 FADD Proteins 0.000 claims 1
- 101700079540 FAS Proteins 0.000 claims 1
- 102100009015 FHIT Human genes 0.000 claims 1
- 101710030892 FLT1 Proteins 0.000 claims 1
- 102100006565 FLT1 Human genes 0.000 claims 1
- 102100006280 FZD7 Human genes 0.000 claims 1
- 101700009028 FZD7 Proteins 0.000 claims 1
- 102100012864 GADD45B Human genes 0.000 claims 1
- 101710037036 GADD45B Proteins 0.000 claims 1
- 102100007247 GSTP1 Human genes 0.000 claims 1
- 101700055920 GSTP1 Proteins 0.000 claims 1
- 102100000579 HGF Human genes 0.000 claims 1
- 108060003679 HHIP Proteins 0.000 claims 1
- 102100016991 HHIP Human genes 0.000 claims 1
- 102100009283 HRAS Human genes 0.000 claims 1
- 101710033925 HRAS Proteins 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- 102100005117 IGF2 Human genes 0.000 claims 1
- 101700070236 IGF2 Proteins 0.000 claims 1
- 102100004102 IGFBP1 Human genes 0.000 claims 1
- 101710031093 IGFBP1 Proteins 0.000 claims 1
- 102100014738 IGFBP3 Human genes 0.000 claims 1
- 101710031099 IGFBP3 Proteins 0.000 claims 1
- 108060003940 IL6 Proteins 0.000 claims 1
- 102100002729 IRS1 Human genes 0.000 claims 1
- 101700048020 IRS1 Proteins 0.000 claims 1
- 102100001478 ITGB1 Human genes 0.000 claims 1
- 101710006661 ITGB1 Proteins 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010022489 Insulin resistance Diseases 0.000 claims 1
- 102100013180 KDR Human genes 0.000 claims 1
- 101700033678 KDR Proteins 0.000 claims 1
- 101710030888 KDR Proteins 0.000 claims 1
- 101710026684 LAPTM4A Proteins 0.000 claims 1
- 102100012475 LDLR Human genes 0.000 claims 1
- 108060004326 LDLR Proteins 0.000 claims 1
- 102100004654 LEF1 Human genes 0.000 claims 1
- 101700081294 LEF1 Proteins 0.000 claims 1
- 102100011688 LPL Human genes 0.000 claims 1
- 101700079880 LPL Proteins 0.000 claims 1
- 101700031439 MCL1 Proteins 0.000 claims 1
- 102100002383 MCL1 Human genes 0.000 claims 1
- 101710010344 MLXIPL Proteins 0.000 claims 1
- 102100012729 MLXIPL Human genes 0.000 claims 1
- 101700079815 MOCS1 Proteins 0.000 claims 1
- 102100013820 MSH2 Human genes 0.000 claims 1
- 101700083509 MSH2 Proteins 0.000 claims 1
- 229910015837 MSH2 Inorganic materials 0.000 claims 1
- 102100005745 MSH3 Human genes 0.000 claims 1
- 108060002317 MSH3 Proteins 0.000 claims 1
- 102100012811 MTDH Human genes 0.000 claims 1
- 101700070364 MTDH Proteins 0.000 claims 1
- 102100019305 MTTP Human genes 0.000 claims 1
- 101710026915 MTTP Proteins 0.000 claims 1
- 102100015262 MYC Human genes 0.000 claims 1
- 101700075357 MYC Proteins 0.000 claims 1
- 102100002692 NFKB1 Human genes 0.000 claims 1
- 101700086102 NFKB1 Proteins 0.000 claims 1
- 102100001119 NRAS Human genes 0.000 claims 1
- 101710033916 NRAS Proteins 0.000 claims 1
- 208000008338 Non-alcoholic Fatty Liver Disease Diseases 0.000 claims 1
- 108009000135 Nonalcoholic fatty liver disease Proteins 0.000 claims 1
- 102100003129 OPCML Human genes 0.000 claims 1
- 101710022656 OPCML Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 101710018349 PDGFRA Proteins 0.000 claims 1
- 102100004940 PDGFRA Human genes 0.000 claims 1
- 108010028924 PPAR alpha Proteins 0.000 claims 1
- 108010016731 PPAR gamma Proteins 0.000 claims 1
- 101710027594 PPARGC1A Proteins 0.000 claims 1
- 102100019039 PPARGC1A Human genes 0.000 claims 1
- 102100008799 PTEN Human genes 0.000 claims 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims 1
- 102100016136 RASSF1 Human genes 0.000 claims 1
- 101710037979 RASSF1 Proteins 0.000 claims 1
- 102100000895 RB1 Human genes 0.000 claims 1
- 101710003919 RB1 Proteins 0.000 claims 1
- 101710017811 RB1 Proteins 0.000 claims 1
- 102100004989 RHOA Human genes 0.000 claims 1
- 101700020165 RHOA Proteins 0.000 claims 1
- 102100013040 RUNX3 Human genes 0.000 claims 1
- 101700072077 RUNX3 Proteins 0.000 claims 1
- 102000035266 SCARB3 Human genes 0.000 claims 1
- 102100008983 SFRP2 Human genes 0.000 claims 1
- 101700038972 SFRP2 Proteins 0.000 claims 1
- 102100017680 SMAD4 Human genes 0.000 claims 1
- 101700062085 SMAD4 Proteins 0.000 claims 1
- 101700026522 SMAD7 Proteins 0.000 claims 1
- 102100000643 SMAD7 Human genes 0.000 claims 1
- 102100005349 SOCS1 Human genes 0.000 claims 1
- 102100014920 SREBF1 Human genes 0.000 claims 1
- 102100019667 STAT3 Human genes 0.000 claims 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims 1
- 108010071390 Serum Albumin Proteins 0.000 claims 1
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 claims 1
- 108010089643 Suppressor of Cytokine Signaling 1 Protein Proteins 0.000 claims 1
- 108010090827 Suppressor of Cytokine Signaling 3 Protein Proteins 0.000 claims 1
- 102000013443 Suppressor of Cytokine Signaling 3 Protein Human genes 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 102100006739 TCF4 Human genes 0.000 claims 1
- 101710006588 TCF4 Proteins 0.000 claims 1
- 101710044572 TCF7L2 Proteins 0.000 claims 1
- 102100008883 TFPT Human genes 0.000 claims 1
- 101700030033 TFPT Proteins 0.000 claims 1
- 101700038204 TGFA Proteins 0.000 claims 1
- 102100014223 TGFA Human genes 0.000 claims 1
- 102100012087 TLR4 Human genes 0.000 claims 1
- 101700022711 TLR4 Proteins 0.000 claims 1
- 101710030970 TNFRSF10B Proteins 0.000 claims 1
- 102100012980 TNFRSF10B Human genes 0.000 claims 1
- 102100002198 TNFSF10 Human genes 0.000 claims 1
- 101710022353 TNFSF10 Proteins 0.000 claims 1
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 claims 1
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 claims 1
- 101700068732 VEGFA Proteins 0.000 claims 1
- 102100015249 VEGFA Human genes 0.000 claims 1
- 102100008060 WT1 Human genes 0.000 claims 1
- 101700062995 WT1 Proteins 0.000 claims 1
- 108010085257 X-Linked Inhibitor of Apoptosis Protein Proteins 0.000 claims 1
- 102100010212 XIAP Human genes 0.000 claims 1
- 102100003679 YAP1 Human genes 0.000 claims 1
- 108060009539 YAP1 Proteins 0.000 claims 1
- 101710010287 YWHAZ Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108010064089 fragile histidine triad protein Proteins 0.000 claims 1
- 101710012090 fruB(HI) Proteins 0.000 claims 1
- 101710032721 fryA Proteins 0.000 claims 1
- 201000004044 liver cirrhosis Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 102000013391 reelin protein Human genes 0.000 claims 1
- 108091007513 reelin protein Proteins 0.000 claims 1
- 230000001105 regulatory Effects 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
Claims (15)
- 細胞での遺伝子の発現を調節するための、C/EBPα転写物を標的とするsaRNAを含む組成物であって、前記遺伝子が、癌遺伝子又は腫瘍抑制遺伝子から選択される組成物。
- 前記遺伝子が癌遺伝子であり、任意選択で、
(i)前記癌遺伝子の発現を低減させ、任意選択で、前記癌遺伝子の発現を少なくとも1倍低減させるか、又は
(ii)前記遺伝子が、ADAM17、AKT1、ANGPT2、BCL2、BCL2L1、BIRC2、BIRC5、CCL5、CCND1、CCND2、CDH1、CDH13、CDKN1A、CDKN1B、CDKN2A、CFLAR、CTNNB1、CXCR4、E2F1、EGF、EGFR、EP300、FADD、FLT1、FZD7、GSTP1、HGF、HRAS、IGFBP1、IGFBP3、IRS1、ITGB1、KDR、MCL1、MET、MSH2、MSH3、MTDH、MYC、NFKB1、NRAS、OPCML、PDGFRA、PIN1、PTGS2、PYCARD、RAC1、RASSF1、RELN、RHOA、SFRP2、SMAD7、SOCS1、STAT3、TCF4、TERT、TGFA、TGFB1、TLR4、TNFRSF10B、VEGFA、WT1、XIAP、及びYAP1からなる群から選択される、請求項1に記載の組成物。 - 前記遺伝子が、腫瘍抑制遺伝子である、請求項1に記載の組成物。
- 前記腫瘍抑制遺伝子の発現を増加させ、任意選択で、前記腫瘍抑制遺伝子の発現を少なくとも1倍増加させる、請求項3に記載の組成物。
- 前記遺伝子が、BAX、BID、CASP8、DAB21P、DLC1、FAS、FHIT、GADD45B、HHIP、IGF2、LEF1、PTEN、PTK2、RB1、RUNX3、SMAD4、SOCS3、TGFBR2、TNFBR2、TNFSF10、及びP53からなる群から選択される、請求項3に記載の組成物。
- 前記saRNAが、配列番号2、4、6、8、10、又は12を含む、請求項1に記載の組成物。
- 過剰増殖性細胞の増殖を低減するための、C/EBPα転写物を標的とするsaRNAを含む組成物であって、任意選択で、
(i)前記過剰増殖性細胞が腫瘍細胞であり、任意選択で、前記過剰増殖性細胞が、肝腫瘍細胞、乳癌細胞、白血病細胞、リンパ腫細胞、肺癌細胞、卵巣癌細胞、又は膵臓癌細胞であるか、又は
(ii)前記saRNAが、配列番号2、4、6、8、10、又は12を含む、組成物。 - 過剰増殖性障害を治療又は予防するための、C/EBPα転写物を標的とするsaRNAを含む組成物であって、任意選択で前記saRNAが配列番号2、4、6、8、10、又は12を含む、組成物。
- 前記過剰増殖性障害が腫瘍であり、任意選択で、
(i)前記腫瘍の量を少なくとも10%低減させるか、又は
(ii)前記腫瘍が、肝細胞癌、乳癌、肺癌、白血病、卵巣癌、及び膵臓癌からなる群から選択される、請求項8に記載の組成物。 - 請求項9の(ii)に記載の組成物であって、前記腫瘍が、
(a)肝細胞癌であるか、又は
(b)乳癌であり、任意選択で、前記組成物がC/EBPβ遺伝子発現を阻害するsiRNAを更に含み、任意選択で前記saRNAが配列番号30又は32を含む、組成物。 - 患者の非アルコール性脂肪肝疾患、硬変症、インスリン抵抗性、又は肥満を治療するための、C/EBPα転写物を標的とするsaRNAを含む組成物であって、任意選択で、
(i)前記患者の肝細胞のLDLレベルを低減させるか、
(ii)前記患者の肝細胞のトリグリセリドレベルを低減させるか、
(iii)前記患者の体重を低減させるか、
(iv)前記患者の肝臓サイズを低減させるか、
(v)FAT/CD36、SREBP1、DGAT2、CETP、FASN、PPARγ−CoA1α、PPARγ−CoA1β、又はMLXIPLの発現を低減させるか、
(vi)LPL、LXD、ACACA、ACACB、APOC3、MTP、LDLR、PGC−1α、PGC−1β、PPARγ、又はPPARαの発現を増加させるか、
(vii)前記saRNAが配列番号2、4、6、8、10、又は12を含むか、
(viii)前記患者の白色脂肪組織を低減させるか、
(ix)前記患者の褐色脂肪組織を活性化させるか、
(x)前記患者の体脂肪を低減させるか、
(xi)前記患者の血清アルブミンレベルを増加させる、組成物。 - C/EBPα転写物を標的とするsaRNA及び少なくとも1つの薬学的に許容される担体を含む医薬組成物であって、任意選択で、
(i)siRNAを更に含み、任意選択で、前記siRNAがC/EBPβ遺伝子発現を阻害するか、
(ii)肝臓のインスリン感受性を増加させるか又はII型糖尿病を治療する薬物を更に含むか、
(iii)肝細胞のLDLレベルを低減させる薬物を更に含むか、
(iv)前記saRNAが、配列番号2、4、6、8、10、又は12を含み、任意選択で、前記担体がデンドリマーであり、任意選択で、前記デンドリマーがポリ(アミドアミン)(PAMAM)である、医薬組成物。 - C/EBPα転写物を標的とするsaRNAであって、フランキング配列を含み、前記フランキング配列がマイクロRNAの配列であり、任意選択で、
(i)前記マイクロRNAが、miR−30であるか、
(ii)前記saRNA配列が配列番号2、4、6、8、10、又は12である、saRNA。 - C/EBPα転写物を標的とするsaRNA及びアプタマーを含む結合体であって、任意選択で、
(i)前記アプタマーがヌクレオチドであるか、
(ii)前記アプタマーがペプチドであるか、
(iii)前記saRNA配列が、配列番号2、4、6、8、10、又は12から選択される配列を含む、結合体。 - 患者のプレB細胞悪性腫瘍及びB細胞悪性腫瘍を治療するための、C/EBPα転写物を標的とするsaRNAを含む組成物であって、任意選択で、前記患者が白血病又はリンパ腫を有する、組成物。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019208538A JP6946399B2 (ja) | 2013-11-22 | 2019-11-19 | C/EBPα低分子活性化RNA |
JP2021150183A JP2022008404A (ja) | 2013-11-22 | 2021-09-15 | C/EBPα小分子活性化RNA組成物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361907732P | 2013-11-22 | 2013-11-22 | |
US61/907,732 | 2013-11-22 | ||
PCT/IB2014/003054 WO2015075557A2 (en) | 2013-11-22 | 2014-11-24 | C/ebp alpha compositions and methods of use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019208538A Division JP6946399B2 (ja) | 2013-11-22 | 2019-11-19 | C/EBPα低分子活性化RNA |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016539127A JP2016539127A (ja) | 2016-12-15 |
JP2016539127A5 true JP2016539127A5 (ja) | 2017-12-14 |
JP6621409B2 JP6621409B2 (ja) | 2019-12-18 |
Family
ID=52649067
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016533569A Active JP6621409B2 (ja) | 2013-11-22 | 2014-11-24 | C/EBPα小分子活性化RNA組成物 |
JP2019208538A Active JP6946399B2 (ja) | 2013-11-22 | 2019-11-19 | C/EBPα低分子活性化RNA |
JP2021150183A Pending JP2022008404A (ja) | 2013-11-22 | 2021-09-15 | C/EBPα小分子活性化RNA組成物 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019208538A Active JP6946399B2 (ja) | 2013-11-22 | 2019-11-19 | C/EBPα低分子活性化RNA |
JP2021150183A Pending JP2022008404A (ja) | 2013-11-22 | 2021-09-15 | C/EBPα小分子活性化RNA組成物 |
Country Status (10)
Country | Link |
---|---|
US (4) | US10202601B2 (ja) |
EP (3) | EP3594348B1 (ja) |
JP (3) | JP6621409B2 (ja) |
KR (3) | KR102507624B1 (ja) |
CN (2) | CN112220797B (ja) |
AU (3) | AU2014351482B2 (ja) |
CA (1) | CA2930973A1 (ja) |
DK (2) | DK3071696T3 (ja) |
SI (2) | SI3071696T1 (ja) |
WO (1) | WO2015075557A2 (ja) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3613852A3 (en) | 2011-07-22 | 2020-04-22 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
US20150166982A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting pi3k point mutations |
EP3084008B1 (en) * | 2013-12-17 | 2018-07-18 | Csir | A method for identification of anti-hiv human mirna mimics and mirna inhibitors and anti-hiv pharmaceutical compounds |
WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
US20160060314A1 (en) | 2014-08-27 | 2016-03-03 | Daewoong Jo | Development of a Protein-Based Biotherapeutic Agent That Penetrates Cell-Membrane and Induces Anti-Tumor Effect in Solid Tumors - Improved Cell-Permeable Suppressor of Cytokine Signaling (iCP-SOCS3) Proteins, Polynucleotides Encoding the Same, and Anti-Tumor Compositions Comprising the Same |
WO2016054094A1 (en) * | 2014-09-30 | 2016-04-07 | Research Institute At Nationwide Children's Hospital | Compositions and methods for treating hepatic fibrosis |
EP3286316A1 (en) * | 2015-04-22 | 2018-02-28 | MiNA Therapeutics Limited | C/ebp alpha sarna compositions and methods of use |
CN114224907A (zh) * | 2015-07-02 | 2022-03-25 | 希望之城 | 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法 |
JP6824966B2 (ja) * | 2015-09-21 | 2021-02-03 | インターセプト ファーマシューティカルズ, インコーポレイテッド | 肝臓の再生を促進する方法 |
JP7109784B2 (ja) | 2015-10-23 | 2022-08-01 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 遺伝子編集のための進化したCas9蛋白質 |
CN106636314B (zh) * | 2015-10-30 | 2020-06-02 | 益善生物技术股份有限公司 | 乳腺癌相关microRNA检测试剂盒 |
CN106636312B (zh) * | 2015-10-30 | 2020-06-02 | 益善生物技术股份有限公司 | 肝癌相关microRNA检测试剂盒 |
CN106636316B (zh) * | 2015-10-30 | 2020-06-02 | 益善生物技术股份有限公司 | 卵巢癌相关microRNA检测试剂盒 |
CN106636313B (zh) * | 2015-10-30 | 2020-06-02 | 益善生物技术股份有限公司 | 胃癌相关microRNA检测试剂盒 |
CN106749655B (zh) * | 2015-11-19 | 2021-01-26 | 中国科学院生物物理研究所 | 一种针对蛋白e2-2的单克隆抗体 |
CN106729750A (zh) * | 2015-11-20 | 2017-05-31 | 昆山彭济凯丰生物科技有限公司 | 通过miR-183治疗高血脂、脂肪肝、二型糖尿病和降低体重的方法和药物及它们的应用 |
EP3254683A1 (en) * | 2016-06-06 | 2017-12-13 | Medizinische Hochschule Hannover | Medicament for the treatment of acute liver failure |
CN106244588B (zh) * | 2016-07-30 | 2019-07-12 | 内蒙古医科大学附属人民医院 | 激活肺癌细胞中RUNX3表达的saRNA及其应用 |
WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
CN106086214A (zh) * | 2016-08-11 | 2016-11-09 | 河南大学 | miR‑149‑5p作为临床诊断或抑制肝癌的应用 |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
WO2018071868A1 (en) | 2016-10-14 | 2018-04-19 | President And Fellows Of Harvard College | Aav delivery of nucleobase editors |
US11332713B2 (en) | 2016-11-16 | 2022-05-17 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
CN110582304A (zh) | 2016-12-08 | 2019-12-17 | 库尔维科公司 | 用于治疗或预防肝脏疾病的rna |
WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
KR20190127797A (ko) | 2017-03-10 | 2019-11-13 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 시토신에서 구아닌으로의 염기 편집제 |
CA3057192A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
CN108938659A (zh) * | 2017-05-19 | 2018-12-07 | 昆山彭济凯丰生物科技有限公司 | 一种调节食欲和体重的方法和药物及它们的应用 |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
EP4219715A3 (en) * | 2017-09-08 | 2023-09-06 | MiNA Therapeutics Limited | Stabilized cebpa sarna compositions and methods of use |
WO2019048631A1 (en) | 2017-09-08 | 2019-03-14 | Mina Therapeutics Limited | SMALL HNF4A ACTIVATOR RNA COMPOSITIONS AND METHODS OF USE |
EP3684375A4 (en) | 2017-09-22 | 2021-09-22 | John Mansell | COMPOSITIONS AND METHODS OF TREATMENT OF SEPSIS-RELATED DISORDERS |
US10676744B2 (en) * | 2017-10-13 | 2020-06-09 | University Of South Carolina | Modulation of adipose tissue macrophage phenotype by use of MicroRNA-30 |
CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
CN107663541A (zh) * | 2017-10-31 | 2018-02-06 | 温州医科大学 | 一种用于诊断原发性肝癌的特异性生物标志物及其筛选方法与应用 |
US11007211B2 (en) * | 2018-01-07 | 2021-05-18 | City Of Hope | CCR7 aptamers and uses thereof |
CN108559750B (zh) * | 2018-01-16 | 2020-07-31 | 华南农业大学 | Stat3在猪卵巢颗粒细胞中的应用 |
WO2019158720A1 (en) | 2018-02-16 | 2019-08-22 | Mina Therapeutics Limited | C/ebp alpha sarna compositions and methods of use |
BR112020018620A2 (pt) | 2018-03-15 | 2020-12-29 | KSQ Therapeutics, Inc. | Composições de regulação gênica e métodos para imunoterapia aprimorada |
CN108959843B (zh) * | 2018-06-06 | 2021-07-06 | 北京箭牧科技有限公司 | 靶向rna的化学小分子药物计算机筛选方法 |
CA3102334A1 (en) * | 2018-06-15 | 2019-12-19 | Mina Therapeutics Limited | Combination therapies comprising c/ebp alpha sarna |
WO2020051243A1 (en) * | 2018-09-04 | 2020-03-12 | Ohio State Innovation Foundation | Lipid nanoparticles and methods of using thereof |
JP2022529562A (ja) * | 2019-01-30 | 2022-06-23 | ラクティゲン セラピューティクス | オリゴヌクレオチド分子及び腫瘍治療におけるその応用 |
CN109837300A (zh) * | 2019-03-04 | 2019-06-04 | 山东省千佛山医院 | 一种用于提高alpps诱导肝组织生长率的方法 |
MX2021011426A (es) | 2019-03-19 | 2022-03-11 | Broad Inst Inc | Metodos y composiciones para editar secuencias de nucleótidos. |
CN113677373A (zh) * | 2019-03-28 | 2021-11-19 | 日东电工株式会社 | RNAi分子 |
CN113950528A (zh) * | 2019-04-24 | 2022-01-18 | 内华达研究与创新公司 | MiR-10模拟物的方法和组合物及其靶标 |
WO2021087234A1 (en) * | 2019-11-01 | 2021-05-06 | The Board Of Trustees Of The Leland Stanford Junior University | Lineage reprogramming as a cancer immunotherapy |
IL297761A (en) | 2020-05-08 | 2022-12-01 | Broad Inst Inc | Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence |
CN112941076B (zh) * | 2021-02-05 | 2023-07-07 | 中国药科大学 | FXR靶向的saRNA及其应用 |
WO2022229644A1 (en) | 2021-04-28 | 2022-11-03 | Mina Therapeutics Limited | Combination therapies comprising c/ebp alpha sarna |
CN114306367B (zh) * | 2021-08-27 | 2023-03-28 | 赵小洋 | 一种含有C/EBPα-saRNA的组合物 |
CN114349841B (zh) * | 2021-10-26 | 2024-02-13 | 安徽农业大学 | 一种调控卵泡膜表面ovr基因表达活性的转录因子及其应用 |
CN114045294B (zh) * | 2021-11-22 | 2023-03-24 | 昆明理工大学 | 一种脂质转运蛋白基因及其应用 |
CN113957157B (zh) * | 2021-12-06 | 2023-10-10 | 湖北省农业科学院畜牧兽医研究所 | 一种与蛋鸡肝脏脂代谢相关的circRNA及其应用 |
CN114469996B (zh) * | 2021-12-23 | 2023-10-20 | 中国医学科学院医学生物学研究所 | 一种包含miR-135b-5p的外泌体及在抗轮状病毒感染中的应用 |
CN114392266B (zh) * | 2022-01-22 | 2022-11-15 | 暨南大学附属第一医院(广州华侨医院) | 包含PPARγ抑制剂的药物组合物及其应用 |
CN114686424B (zh) * | 2022-03-09 | 2023-09-22 | 海南医学院 | 一种调控C/EBPα基因表达的方法及C/EBPα表达抑制剂 |
WO2023214405A1 (en) * | 2022-05-01 | 2023-11-09 | Yeda Research And Development Co. Ltd. | Reexpression of hnf4a to alleviate cancer-associated cachexia |
Family Cites Families (187)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5927900A (ja) | 1982-08-09 | 1984-02-14 | Wakunaga Seiyaku Kk | 固定化オリゴヌクレオチド |
FR2540122B1 (fr) | 1983-01-27 | 1985-11-29 | Centre Nat Rech Scient | Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application |
US4605735A (en) | 1983-02-14 | 1986-08-12 | Wakunaga Seiyaku Kabushiki Kaisha | Oligonucleotide derivatives |
US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
US4824941A (en) | 1983-03-10 | 1989-04-25 | Julian Gordon | Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems |
US4587044A (en) | 1983-09-01 | 1986-05-06 | The Johns Hopkins University | Linkage of proteins to nucleic acids |
US5118802A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside |
US5258506A (en) | 1984-10-16 | 1993-11-02 | Chiron Corporation | Photolabile reagents for incorporation into oligonucleotide chains |
US5430136A (en) | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
US4828979A (en) | 1984-11-08 | 1989-05-09 | Life Technologies, Inc. | Nucleotide analogs for nucleic acid labeling and detection |
US4762779A (en) | 1985-06-13 | 1988-08-09 | Amgen Inc. | Compositions and methods for functionalizing nucleic acids |
US5317098A (en) | 1986-03-17 | 1994-05-31 | Hiroaki Shizuya | Non-radioisotope tagging of fragments |
JPS638396A (ja) | 1986-06-30 | 1988-01-14 | Wakunaga Pharmaceut Co Ltd | ポリ標識化オリゴヌクレオチド誘導体 |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
US5525465A (en) | 1987-10-28 | 1996-06-11 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates and methods of production and applications of the same |
DE3738460A1 (de) | 1987-11-12 | 1989-05-24 | Max Planck Gesellschaft | Modifizierte oligonukleotide |
US5082830A (en) | 1988-02-26 | 1992-01-21 | Enzo Biochem, Inc. | End labeled nucleotide probe |
US5109124A (en) | 1988-06-01 | 1992-04-28 | Biogen, Inc. | Nucleic acid probe linked to a label having a terminal cysteine |
US5262536A (en) | 1988-09-15 | 1993-11-16 | E. I. Du Pont De Nemours And Company | Reagents for the preparation of 5'-tagged oligonucleotides |
US5512439A (en) | 1988-11-21 | 1996-04-30 | Dynal As | Oligonucleotide-linked magnetic particles and uses thereof |
US5599923A (en) | 1989-03-06 | 1997-02-04 | Board Of Regents, University Of Tx | Texaphyrin metal complexes having improved functionalization |
US5457183A (en) | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
US4958013A (en) | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
US5451463A (en) | 1989-08-28 | 1995-09-19 | Clontech Laboratories, Inc. | Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides |
US5254469A (en) | 1989-09-12 | 1993-10-19 | Eastman Kodak Company | Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures |
US5292873A (en) | 1989-11-29 | 1994-03-08 | The Research Foundation Of State University Of New York | Nucleic acids labeled with naphthoquinone probe |
US5486603A (en) | 1990-01-08 | 1996-01-23 | Gilead Sciences, Inc. | Oligonucleotide having enhanced binding affinity |
US5578718A (en) | 1990-01-11 | 1996-11-26 | Isis Pharmaceuticals, Inc. | Thiol-derivatized nucleosides |
AU7579991A (en) | 1990-02-20 | 1991-09-18 | Gilead Sciences, Inc. | Pseudonucleosides and pseudonucleotides and their polymers |
US5214136A (en) | 1990-02-20 | 1993-05-25 | Gilead Sciences, Inc. | Anthraquinone-derivatives oligonucleotides |
ES2116977T3 (es) | 1990-05-11 | 1998-08-01 | Microprobe Corp | Soportes solidos para ensayos de hibridacion de acidos nucleicos y metodos para inmovilizar oligonucleotidos de modo covalente. |
US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
US5218105A (en) | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
US5688941A (en) | 1990-07-27 | 1997-11-18 | Isis Pharmaceuticals, Inc. | Methods of making conjugated 4' desmethyl nucleoside analog compounds |
US5245022A (en) | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
US5512667A (en) | 1990-08-28 | 1996-04-30 | Reed; Michael W. | Trifunctional intermediates for preparing 3'-tailed oligonucleotides |
ATE198598T1 (de) | 1990-11-08 | 2001-01-15 | Hybridon Inc | Verbindung von mehrfachreportergruppen auf synthetischen oligonukleotiden |
US5371241A (en) | 1991-07-19 | 1994-12-06 | Pharmacia P-L Biochemicals Inc. | Fluorescein labelled phosphoramidites |
US5565552A (en) | 1992-01-21 | 1996-10-15 | Pharmacyclics, Inc. | Method of expanded porphyrin-oligonucleotide conjugate synthesis |
US5595726A (en) | 1992-01-21 | 1997-01-21 | Pharmacyclics, Inc. | Chromophore probe for detection of nucleic acid |
US5272250A (en) | 1992-07-10 | 1993-12-21 | Spielvogel Bernard F | Boronated phosphoramidate compounds |
US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US5597696A (en) | 1994-07-18 | 1997-01-28 | Becton Dickinson And Company | Covalent cyanine dye oligonucleotide conjugates |
US5580731A (en) | 1994-08-25 | 1996-12-03 | Chiron Corporation | N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US6086913A (en) | 1995-11-01 | 2000-07-11 | University Of British Columbia | Liposomal delivery of AAV vectors |
US20030073640A1 (en) | 1997-07-23 | 2003-04-17 | Ribozyme Pharmaceuticals, Inc. | Novel compositions for the delivery of negatively charged molecules |
JPH1160625A (ja) | 1997-08-22 | 1999-03-02 | Idemitsu Petrochem Co Ltd | オレフィン重合用固体触媒成分、オレフィン重合用触 媒及びオレフィン重合体の製造方法 |
EP1023048B1 (en) | 1997-10-10 | 2007-03-07 | Inex Pharmaceuticals Corp. | Methods for encapsulating nucleic acids in lipid bilayers |
WO2000016782A1 (en) | 1998-09-18 | 2000-03-30 | The University Of British Columbia | Pharmaceutical compositions of vanadium biguanide complexes and their use |
EP1854880A1 (en) | 1999-03-15 | 2007-11-14 | University of British Columbia | Methods and reagents for modulating cholesterol levels |
US8193330B2 (en) | 1999-04-06 | 2012-06-05 | The Regents Of The University Of California | Polynucleotides comprising Neurogenin3 promoter and bHLH encoding domains |
US7094423B1 (en) | 1999-07-15 | 2006-08-22 | Inex Pharmaceuticals Corp. | Methods for preparation of lipid-encapsulated therapeutic agents |
US7189705B2 (en) | 2000-04-20 | 2007-03-13 | The University Of British Columbia | Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers |
US6306655B1 (en) | 2000-06-13 | 2001-10-23 | Isis Pharmaceuticals, Inc. | Antisense inhibition of C/EBP alpha expression |
US6998115B2 (en) | 2000-10-10 | 2006-02-14 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
CA2426244A1 (en) | 2000-10-25 | 2002-05-02 | The University Of British Columbia | Lipid formulations for target delivery |
EP1392714B1 (en) | 2001-03-12 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Steroids as agonists for fxr |
CA2462593A1 (en) | 2001-10-03 | 2003-04-10 | Kam W. Leong | Compositions for oral gene therapy and methods of using same |
US7223887B2 (en) | 2001-12-18 | 2007-05-29 | The University Of British Columbia | Multivalent cationic lipids and methods of using same in the production of lipid particles |
DE10207178A1 (de) | 2002-02-19 | 2003-09-04 | Novosom Ag | Komponenten für die Herstellung amphoterer Liposomen |
US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
AU2003217531A1 (en) | 2002-05-02 | 2003-11-17 | Massachusetts Eye And Ear Infirmary | Ocular drug delivery systems and use thereof |
JP4868739B2 (ja) | 2002-05-06 | 2012-02-01 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 核酸の送達法 |
JP2006507841A (ja) | 2002-11-14 | 2006-03-09 | ダーマコン, インコーポレイテッド | 機能的siRNAおよび超機能的siRNA |
EP1568706A1 (en) | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
ATE536418T1 (de) | 2004-06-07 | 2011-12-15 | Protiva Biotherapeutics Inc | Lipidverkapselte interferenz-rna |
EP1791567B1 (en) | 2004-08-10 | 2015-07-29 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
US20060252670A1 (en) | 2004-10-14 | 2006-11-09 | Intercept Pharmaceuticals Inc. | Method of reducing drug-induced adverse side effects in a patient |
US8192718B1 (en) | 2005-01-04 | 2012-06-05 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
WO2007086883A2 (en) | 2005-02-14 | 2007-08-02 | Sirna Therapeutics, Inc. | Cationic lipids and formulated molecular compositions containing them |
US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
ES2332062T3 (es) | 2005-04-01 | 2010-01-25 | Intezyne Technologies Incorporated | Micelas polimericas para el suministro de farmacos. |
WO2006113246A2 (en) | 2005-04-15 | 2006-10-26 | The Regents Of The University Of California | Small activating rna molecules and methods of use |
ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
US8357666B2 (en) | 2005-08-01 | 2013-01-22 | Nupotential, Inc. | Reprogramming a cell by inducing a pluripotent gene through RNA interference |
JP2007082430A (ja) | 2005-09-20 | 2007-04-05 | Niigata Univ | 脳腫瘍マーカーおよびその用途 |
EP1939252B1 (en) | 2005-10-20 | 2011-09-21 | Asahi Glass Company, Limited | Aqueous polytetrafluoroethylene dispersion and product made from same |
EP1957648B1 (en) | 2005-11-17 | 2014-04-23 | Board of Regents, The University of Texas System | Modulation of gene expression by oligomers targeted to chromosomal dna |
CN101437933B (zh) | 2005-12-28 | 2013-11-06 | 斯克里普斯研究所 | 作为药物靶标的天然反义和非编码的rna转录物 |
EP1987051A2 (en) | 2006-02-14 | 2008-11-05 | Intercept Pharmaceuticals, Inc. | Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions |
PL2040713T3 (pl) | 2006-06-27 | 2014-11-28 | Intercept Pharmaceuticals Inc | Pochodne kwasów żółciowych jako ligandy FXR do zapobiegania lub leczenia chorób lub stanów, w których pośredniczy FXR |
DK2068886T3 (da) | 2006-10-03 | 2013-11-18 | Tekmira Pharmaceuticals Corp | Lipidholdige præparater |
JP5424885B2 (ja) | 2006-10-13 | 2014-02-26 | マリーナ バイオテック,インコーポレイテッド | 両性リポソームにおけるまたは両性リポソームに関する改善、両性リポソームを処方する方法および両性リポソームに充填する方法 |
JP5292310B2 (ja) | 2007-01-19 | 2013-09-18 | インターセプト ファーマシューティカルズ, インコーポレイテッド | Tgr5調節剤としての23−置換胆汁酸およびその使用方法 |
WO2008103276A2 (en) | 2007-02-16 | 2008-08-28 | Merck & Co., Inc. | Compositions and methods for potentiated activity of biologicaly active molecules |
US8258267B2 (en) | 2007-02-28 | 2012-09-04 | Novimmune S.A. | Human anti-IP-10 antibodies uses thereof |
WO2008109556A1 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting telomerase gene expression and uses thereof |
US20100041140A1 (en) | 2007-03-02 | 2010-02-18 | Mdrna, Inc. | Nucleic acid compounds for inhibiting bcl2 gene expression and uses thereof |
EP2136788B1 (en) | 2007-03-30 | 2011-10-26 | Bind Biosciences, Inc. | Cancer cell targeting using nanoparticles |
WO2008150814A2 (en) | 2007-05-29 | 2008-12-11 | Reid Christopher B | Methods for production and uses of multipotent cell populations |
WO2009046397A2 (en) | 2007-10-04 | 2009-04-09 | Board Of Regents, The University Of Texas System | Modulating gene expression with agrna and gapmers targeting antisense transcripts |
EP2235033A4 (en) | 2007-12-28 | 2011-11-02 | Univ California | METHOD AND COMPOSITIONS FOR INCREASING GENE EXPRESSION |
EP2105145A1 (en) | 2008-03-27 | 2009-09-30 | ETH Zürich | Method for muscle-specific delivery lipid-conjugated oligonucleotides |
WO2009126250A2 (en) | 2008-04-07 | 2009-10-15 | Nupotential, Inc. | Reprogramming a cell by inducing a pluripotent gene through rna interference |
WO2009126927A2 (en) | 2008-04-11 | 2009-10-15 | Joslin Diabetes Center, Inc. | Methods of generating insulin-producing cells |
EP2274425A2 (en) | 2008-04-11 | 2011-01-19 | Alnylam Pharmaceuticals Inc. | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
AU2009238175C1 (en) | 2008-04-15 | 2023-11-30 | Arbutus Biopharma Corporation | Novel lipid formulations for nucleic acid delivery |
WO2009132131A1 (en) | 2008-04-22 | 2009-10-29 | Alnylam Pharmaceuticals, Inc. | Amino lipid based improved lipid formulation |
AU2009268923B2 (en) | 2008-06-16 | 2015-09-17 | Pfizer Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
JP2012501966A (ja) | 2008-06-16 | 2012-01-26 | バインド バイオサイエンシズ インコーポレイテッド | ビンカアルカロイド含有治療用ポリマーナノ粒子並びにその製造方法及び使用方法 |
EP2285350B1 (en) | 2008-06-16 | 2017-11-15 | Pfizer Inc | Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic nanoparticles |
WO2010014836A2 (en) | 2008-07-30 | 2010-02-04 | Intercept Pharmaceuticals, Inc. | Tgr5 modulators and methods of use thereof |
US20110224447A1 (en) | 2008-08-18 | 2011-09-15 | Bowman Keith A | Novel Lipid Nanoparticles and Novel Components for Delivery of Nucleic Acids |
WO2010030763A2 (en) | 2008-09-10 | 2010-03-18 | Bind Biosciences, Inc. | High throughput fabrication of nanoparticles |
JP5529142B2 (ja) | 2008-09-25 | 2014-06-25 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 血清アミロイドa遺伝子の発現を阻害するための脂質製剤組成物および方法 |
AU2009303345B2 (en) | 2008-10-09 | 2015-08-20 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
CN102264898B (zh) | 2008-10-23 | 2013-10-16 | 国立大学法人东京大学 | 微小rna的功能抑制方法 |
NZ602474A (en) | 2008-11-13 | 2013-02-22 | Baylor Res Inst | Regeneration of pancreatic islets and reversal of diabetes by islet transcription factor genes delivered in vivo |
MX2011005295A (es) | 2008-11-19 | 2011-06-24 | Intercept Pharmaceuticals Inc | Moduladores de tgr5 y metodo de uso de los mismos. |
JP2012512175A (ja) | 2008-12-15 | 2012-05-31 | バインド バイオサイエンシズ インコーポレイテッド | 治療薬を徐放するための長時間循環性ナノ粒子 |
US9181315B2 (en) * | 2009-01-08 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for induced brown fat differentiation |
WO2010080724A1 (en) | 2009-01-12 | 2010-07-15 | Merck Sharp & Dohme Corp. | Novel lipid nanoparticles and novel components for delivery of nucleic acids |
JP5596712B2 (ja) | 2009-03-12 | 2014-09-24 | イリノイ トゥール ワークス インコーポレイティド | 給油ミス防止装置 |
WO2010108126A2 (en) | 2009-03-19 | 2010-09-23 | Fate Therapeutics, Inc. | Reprogramming compositions and methods of using the same |
JP5622254B2 (ja) | 2009-03-31 | 2014-11-12 | 国立大学法人東京大学 | 二本鎖リボ核酸ポリイオンコンプレックス |
EP2421972A2 (en) | 2009-04-24 | 2012-02-29 | The Board of Regents of The University of Texas System | Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions |
WO2010127159A2 (en) | 2009-04-30 | 2010-11-04 | Intezyne Technologies, Incorporated | Polymeric micelles for polynucleotide encapsulation |
JP5769701B2 (ja) | 2009-05-05 | 2015-08-26 | テクミラ ファーマシューティカルズ コーポレイションTekmira Pharmaceuticals Corporation | 脂質組成物 |
CN102575251B (zh) | 2009-05-18 | 2018-12-04 | 库尔纳公司 | 通过抑制针对重编程因子的天然反义转录物来治疗重编程因子相关的疾病 |
AU2010254550B2 (en) | 2009-05-27 | 2015-10-15 | Selecta Biosciences, Inc. | Targeted synthetic nanocarriers with pH sensitive release of immunomodulatory agents |
DK2440183T3 (en) | 2009-06-10 | 2018-10-01 | Arbutus Biopharma Corp | Improved lipid formulation |
US9051567B2 (en) | 2009-06-15 | 2015-06-09 | Tekmira Pharmaceuticals Corporation | Methods for increasing efficacy of lipid formulated siRNA |
US8962583B2 (en) | 2009-06-25 | 2015-02-24 | The Brigham And Women's Hospital, Inc. | Treatment of inflammatory diseases using miR-124 |
WO2011000106A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Improved cationic lipids and methods for the delivery of therapeutic agents |
CA2767127A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
CN101941001B (zh) | 2009-07-03 | 2014-04-02 | 3M创新有限公司 | 亲水涂层、制品、涂料组合物和方法 |
MX340952B (es) | 2009-07-20 | 2016-07-29 | Janssen Biotech Inc | Diferenciacion de celulas madre embrionarias humanas. |
WO2011020023A2 (en) | 2009-08-14 | 2011-02-17 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus |
WO2011022460A1 (en) | 2009-08-20 | 2011-02-24 | Merck Sharp & Dohme Corp. | Novel cationic lipids with various head groups for oligonucleotide delivery |
US20120264810A1 (en) | 2009-09-22 | 2012-10-18 | The University Of British Columbia | Compositions and methods for enhancing cellular uptake and intracellular delivery of lipid particles |
EP2485770A4 (en) | 2009-10-08 | 2013-04-10 | Merck Sharp & Dohme | NEW CATIONIC LIPIDS WITH SHORT LIPID CHAINS FOR ADMINISTRATION OF OLIGONUCLEOTIDES |
WO2011056682A1 (en) | 2009-10-27 | 2011-05-12 | The University Of British Columbia | Reverse head group lipids, lipid particle compositions comprising reverse headgroup lipids, and methods for the delivery of nucleic acids |
RU2573409C2 (ru) | 2009-11-04 | 2016-01-20 | Дзе Юниверсити Оф Бритиш Коламбиа | Содержащие нуклеиновые кислоты липидные частицы и относящиеся к ним способы |
US9687550B2 (en) | 2009-12-07 | 2017-06-27 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
ES2721898T3 (es) | 2009-12-11 | 2019-08-06 | Pfizer | Formulaciones estables para liofilizar partículas terapéuticas |
WO2011084513A2 (en) | 2009-12-15 | 2011-07-14 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
JP5898627B2 (ja) | 2009-12-15 | 2016-04-06 | バインド セラピューティックス インコーポレイテッド | エポチロンを含む治療用ポリマーナノ粒子ならびにそれを製造および使用する方法 |
EP2512487A4 (en) | 2009-12-15 | 2013-08-07 | THERAPEUTIC POLYMERNANOPARTICLES WITH CORTICOSTEROIDS AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
ES2749426T3 (es) | 2009-12-18 | 2020-03-20 | Univ British Columbia | Métodos y composiciones para administración de ácidos nucleicos |
EP2521785B1 (en) | 2010-01-06 | 2022-03-09 | CuRNA, Inc. | Inhibition of natural antisense transcript to a pancreatic developmental gene for use in a treatment of pancreatic developmental gene related diseases |
EP2525781A1 (en) | 2010-01-22 | 2012-11-28 | Schering Corporation | Novel cationic lipids for oligonucleotide delivery |
WO2011127255A1 (en) | 2010-04-08 | 2011-10-13 | Merck Sharp & Dohme Corp. | Preparation of lipid nanoparticles |
US20110262491A1 (en) | 2010-04-12 | 2011-10-27 | Selecta Biosciences, Inc. | Emulsions and methods of making nanocarriers |
US20130156845A1 (en) | 2010-04-29 | 2013-06-20 | Alnylam Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
WO2011143230A1 (en) | 2010-05-10 | 2011-11-17 | Alnylam Pharmaceuticals | Methods and compositions for delivery of active agents |
WO2011149733A2 (en) | 2010-05-24 | 2011-12-01 | Merck Sharp & Dohme Corp. | Novel amino alcohol cationic lipids for oligonucleotide delivery |
JP5957646B2 (ja) | 2010-06-04 | 2016-07-27 | サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. | オリゴヌクレオチド送達のための新規な低分子量カチオン性脂質 |
GB201010557D0 (en) | 2010-06-23 | 2010-08-11 | Mina Therapeutics Ltd | RNA molecules and uses thereof |
DE102010032758B4 (de) | 2010-07-29 | 2012-02-23 | Fujitsu Technology Solutions Intellectual Property Gmbh | Computersystem, Verfahren zum Programmieren einer Echtzeituhr und Computerprogrammprodukt |
WO2012016184A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
US20130202652A1 (en) | 2010-07-30 | 2013-08-08 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
EP2449113B8 (en) | 2010-07-30 | 2015-11-25 | CureVac AG | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
EP2618847A4 (en) | 2010-09-20 | 2014-04-02 | Merck Sharp & Dohme | NOVEL CATIONIC LIPIDS WITH LOW MOLECULAR WEIGHT FOR OLIGONUCLEOTIDE DELIVERY |
WO2012047656A1 (en) | 2010-09-27 | 2012-04-12 | The University Of British Columbia | Lipid a analog compositions |
CN103260611A (zh) | 2010-09-30 | 2013-08-21 | 默沙东公司 | 用于寡核苷酸递送的低分子量阳离子脂质 |
EP2625272B1 (en) | 2010-10-08 | 2015-09-16 | Mina Therapeutics Limited | Methods of inducing insulin production |
EP2629802B1 (en) | 2010-10-21 | 2019-12-04 | Sirna Therapeutics, Inc. | Low molecular weight cationic lipids for oligonucleotide delivery |
US20150056300A1 (en) | 2010-10-22 | 2015-02-26 | Bind Therapeutics, Inc. | Therapeutic nanoparticles with high molecular weight copolymers |
WO2012061259A2 (en) | 2010-11-05 | 2012-05-10 | Merck Sharp & Dohme Corp. | Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery |
AU2011325956B2 (en) * | 2010-11-12 | 2016-07-14 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
CN102584756B (zh) * | 2010-12-23 | 2015-01-21 | 财团法人食品工业发展研究所 | 新颖紫红曲酮、其制备方法及紫红曲酮的用途 |
WO2012092552A1 (en) | 2010-12-30 | 2012-07-05 | Selecta Biosciences, Inc. | Synthetic nanocarriers with reactive groups that release biologically active agents |
AU2012207606B2 (en) | 2011-01-11 | 2017-02-23 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
DE102011082231A1 (de) | 2011-01-12 | 2012-07-12 | Robert Bosch Gmbh | Zündspule, insbesondere für kleinbauende Motoren |
US20140066363A1 (en) | 2011-02-07 | 2014-03-06 | Arun K. Bhunia | Carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide |
CA2830948A1 (en) | 2011-03-25 | 2012-10-04 | Selecta Biosciences, Inc. | Osmotic mediated release synthetic nanocarriers |
US10941399B2 (en) | 2011-04-14 | 2021-03-09 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for gene-specific demethylation by DNA methyltransferase (DNMT)-RNA interaction |
WO2012149393A2 (en) | 2011-04-29 | 2012-11-01 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells |
WO2012166923A2 (en) | 2011-05-31 | 2012-12-06 | Bind Biosciences | Drug loaded polymeric nanoparticles and methods of making and using same |
EP4043025A1 (en) | 2011-06-08 | 2022-08-17 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
CN103748078B (zh) | 2011-06-08 | 2016-11-09 | 夏尔人类遗传性治疗公司 | 可裂解脂质 |
JP6188686B2 (ja) | 2011-06-09 | 2017-08-30 | カッパーアールエヌエー,インコーポレイテッド | フラタキシン(fxn)への天然アンチセンス転写物の阻害によるfxn関連疾患の治療 |
CN103842508B (zh) | 2011-06-21 | 2016-02-24 | 米纳治疗有限公司 | 白蛋白产生和细胞增殖 |
ES2861428T3 (es) | 2011-07-06 | 2021-10-06 | Glaxosmithkline Biologicals Sa | Liposomas que presentan una relación N:P útil para suministro de moléculas de ARN |
AU2012290306B2 (en) | 2011-07-29 | 2017-08-17 | Selecta Biosciences, Inc. | Synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte (CTL) immune responses |
CA2850624A1 (en) | 2011-10-03 | 2013-04-11 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
EP2788316B1 (en) | 2011-12-07 | 2019-04-24 | Alnylam Pharmaceuticals, Inc. | Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents |
ES2921724T1 (es) | 2011-12-07 | 2022-08-31 | Alnylam Pharmaceuticals Inc | Lípidos biodegradables para la administración de agentes activos |
KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
EP2925328A1 (en) | 2012-11-28 | 2015-10-07 | Intercept Pharmaceuticals, Inc. | Treatment of pulmonary disease |
-
2014
- 2014-11-24 CA CA2930973A patent/CA2930973A1/en active Pending
- 2014-11-24 CN CN202011114478.9A patent/CN112220797B/zh active Active
- 2014-11-24 WO PCT/IB2014/003054 patent/WO2015075557A2/en active Application Filing
- 2014-11-24 EP EP19190263.4A patent/EP3594348B1/en active Active
- 2014-11-24 KR KR1020217011610A patent/KR102507624B1/ko active IP Right Grant
- 2014-11-24 KR KR1020237007367A patent/KR20230037686A/ko not_active Application Discontinuation
- 2014-11-24 AU AU2014351482A patent/AU2014351482B2/en active Active
- 2014-11-24 EP EP14843226.3A patent/EP3071696B1/en active Active
- 2014-11-24 SI SI201431310T patent/SI3071696T1/sl unknown
- 2014-11-24 EP EP21195084.5A patent/EP3985118A1/en active Pending
- 2014-11-24 US US15/038,332 patent/US10202601B2/en active Active
- 2014-11-24 DK DK14843226.3T patent/DK3071696T3/da active
- 2014-11-24 SI SI201431918T patent/SI3594348T1/sl unknown
- 2014-11-24 DK DK19190263.4T patent/DK3594348T3/da active
- 2014-11-24 CN CN201480073877.1A patent/CN107075515B/zh active Active
- 2014-11-24 JP JP2016533569A patent/JP6621409B2/ja active Active
- 2014-11-24 KR KR1020167013652A patent/KR102252561B1/ko active IP Right Grant
-
2018
- 2018-12-19 US US16/224,863 patent/US10633659B2/en active Active
-
2019
- 2019-11-19 JP JP2019208538A patent/JP6946399B2/ja active Active
-
2020
- 2020-03-10 US US16/814,210 patent/US20200318114A1/en not_active Abandoned
- 2020-11-18 AU AU2020270508A patent/AU2020270508B2/en active Active
-
2021
- 2021-09-15 JP JP2021150183A patent/JP2022008404A/ja active Pending
-
2022
- 2022-12-23 US US18/088,395 patent/US20240124874A1/en active Pending
-
2023
- 2023-02-21 AU AU2023201019A patent/AU2023201019A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016539127A5 (ja) | ||
Dua et al. | The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress | |
Xie et al. | MicroRNAs as regulators, biomarkers and therapeutic targets in the drug resistance of colorectal cancer | |
Daige et al. | Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer | |
Xie et al. | MicroRNAs associated with HBV infection and HBV-related HCC | |
CN107075515B (zh) | C/EBPα组合物和使用方法 | |
IL290102B2 (en) | Viral vectors of cell lysis and their uses | |
Soriano et al. | microRNAs as pharmacological targets in cancer | |
CN107921147B (zh) | 一种新的前体miRNA及其在肿瘤治疗中的应用 | |
JP7360705B2 (ja) | miRNAを含むがん治療用医薬組成物 | |
US20160145624A1 (en) | LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME | |
Khalife et al. | MicroRNAs in breast cancer: New maestros defining the melody | |
US20160168573A1 (en) | LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME | |
Lei et al. | MicroRNA-based therapy for glioblastoma: Opportunities and challenges | |
US9217149B2 (en) | Pharmaceutical composition for treating cancer | |
AU2021413862A1 (en) | Template directed immunomodulation for cancer therapy | |
KR20150096304A (ko) | 이중가닥 마이크로 rna를 유효성분으로 포함하는 암 예방용 또는 치료용 조성물 | |
WO2021234647A1 (ko) | 이중가닥 올리고뉴클레오티드 및 이를 포함하는 코로나바이러스감염증-19(covid-19) 치료용 조성물 | |
Wang et al. | miR-153 Targets Autophagy and Apoptosis Caspase Family to Explore the Molecular Mechanism of Polystyrene Nanoparticles Intervening in Thoracoabdominal Aortic Aneurysm | |
Davodabadi et al. | Nanotherapeutic approaches for delivery of long non-coding RNAs: an updated review with emphasis on cancer | |
Caetano | MicroRNA Modulation in Combination with Chemotherapeutic Drugs as a Novel Therapeutic Strategy for Pancreatic Cancer | |
JP2023085547A (ja) | snoRNAの発現抑制剤を有効成分とするがん増殖抑制剤 | |
JP2023525168A (ja) | アンフィレギュリン特異的な二本鎖オリゴヌクレオチド構造体を含む肥満関連疾患の予防及び治療用組成物 | |
Milani | Emerging strategies for selective targeting in therapeutic approaches against gliomas | |
HUSSEIN MOHAMMED AHMED ALI | A novel in vivo nanoparticle-mediated delivery for microRNA in a CLL mouse model: identification of miR-26a as a potential therapeutic agent |